MétaCan
Menu
Back to cohort
Record W4417530895 · doi:10.1016/j.esmorc.2025.100055

IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)

2025· article· en· W4417530895 on OpenAlexfundno aff

Bibliographic record

VenueESMO rare cancers. · 2025
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsnot available
FundersDuke Cancer InstituteNational Cancer InstituteKnight Cancer Institute, Oregon Health and Science UniversityUniversity of Texas MD Anderson Cancer CenterUniversity of California, IrvineUSC Norris Comprehensive Cancer CenterMcGill University Health CentreHuntsman Cancer InstituteMcGill UniversityRoyal Marsden NHS Foundation TrustMedical Center, University of PittsburghUniversity of PittsburghWashington University in St. LouisMoffitt Cancer CenterCentre Hospitalier Universitaire de BordeauxUniversity of Southern CaliforniaNational Institutes of HealthOhio State UniversityMemorial Sloan-Kettering Cancer CenterChildren's Hospital of Philadelphia
KeywordsNivolumabIfosfamideEpirubicinSarcomaFirst lineChemotherapy

Abstract

fetched live from OpenAlex

Anthracycline-based chemotherapy (CHT) plus anti-PD1 (nivolumab) could enhance the activity of upfront CHT in advanced UPS, based on a double-hit in the immunogenic cell death circuit. We previously reported a phase Ib trial in leiomyosarcoma patients (pts) with the combination of doxorubicin, dacarbazine, and nivolumab, obtaining 56.5% of ORR. We present here the phase Ib, cohort 7a, of the ImmunoSarc2 trial.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.319
Teacher spread0.298 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueESMO rare cancers.Same topicMultiple Myeloma Research and TreatmentsFrench-language works237,207